Welcome to the PrBIMZELX® patient website
This website is intended only for people who live in Canada and have been prescribed BIMZELX (also called bimekizumab).
The website offers a range of resources designed to support patients and includes injection instructions, frequently asked questions and other useful information.
To enter the website, please enter the BIMZELX Drug Identification Number (DIN) in the login form on the right.
Get Started
Enter the DIN number
If you would like to learn more about psoriasis, visit https://ucbcares.ca/patients/psoriasis/en-CA.
For more information about UCB Canada Inc., visit https://www.ucb-canada.ca/en/Home.
This site is intended for Canadian residents only. The content on this site is not meant to replace the guidance of a healthcare professional.
BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Please consult the Product Monograph at https://ucb-canada.ca/sites/default/files/2022-03/bimekizumab-pm-en-non-nds_14%20Feb%202022.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-866-709-8444.
BIMZELX, UCB, and the UCB logo are registered trademarks of the UCB Group of Companies.
UCBCares is a trademark of the UCB Group of Companies.
© 2022 UCB Canada Inc. All rights reserved.
Send your Feedback!
Would you recommend the UCBCares website to other visitors?